id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-1996-N-0006-0015,FDA,FDA-1996-N-0006,OMB Revisions of the Final Rule re Additional Criteria for Classifying OTC Drugs as Generally Recognized as Safe and Effective; Final Rule,Supporting & Related Material,Reference (internal unless indicated),2002-09-20T04:00:00Z,2002,9,,,2015-03-19T15:17:07Z,,0,0,09000064804f9978
FDA-1996-N-0006-0014,FDA,FDA-1996-N-0006,Reference 1 FDA/CDER re Additional Criteria for Classifying OTC Drugs as Generally Recognized as Safe and Effective; Final Rule,Supporting & Related Material,Reference (internal unless indicated),2002-09-20T04:00:00Z,2002,9,,,2015-03-19T15:21:48Z,,0,0,09000064804f9977
FDA-1996-N-0006-0013,FDA,FDA-1996-N-0006,Letter from FDA/CDER to Ciba Specialty Chemicals,Other,Letter(s),2002-07-17T04:00:00Z,2002,7,,,2015-03-19T18:07:53Z,,0,0,09000064804f9976
FDA-1996-N-0006-0005,FDA,FDA-1996-N-0006,Response Letter from FDA/CDER to Buchanan Ingersoll Professional Corporation,Other,Letter(s),2002-06-26T04:00:00Z,2002,6,,,2015-03-19T18:40:20Z,,0,0,09000064804f9969
FDA-1996-N-0006-0010,FDA,FDA-1996-N-0006,Letter from FDA/CDER to Ciba Specialty Chemicals,Other,Letter(s),2002-06-26T04:00:00Z,2002,6,,,2015-03-20T13:54:01Z,,0,0,09000064804f9973
FDA-1996-N-0006-0009,FDA,FDA-1996-N-0006,Letter from FDA/CDER to Rural Industries Research & Development Corporation,Other,Letter(s),2002-06-26T04:00:00Z,2002,6,,,2015-06-19T20:38:35Z,,0,0,09000064804f9972
FDA-1996-N-0006-0007,FDA,FDA-1996-N-0006,"Response from FDA/CDER to Bass & Ullman, P.C.",Other,Letter(s),2002-06-26T04:00:00Z,2002,6,,,2015-06-19T20:38:06Z,,0,0,09000064804f996e
FDA-1996-N-0006-0006,FDA,FDA-1996-N-0006,"Response from FDA/CDER to BASF AG [Morgan, Lewis & Bockius, LLP]",Other,Letter(s),2002-06-26T04:00:00Z,2002,6,,,2015-03-19T20:19:26Z,,0,0,09000064804f996d
FDA-1996-N-0006-0011,FDA,FDA-1996-N-0006,"Letter from FDA/CDER to EM Industries, Inc.",Other,Letter(s),2002-06-26T04:00:00Z,2002,6,,,2015-03-19T17:39:10Z,,0,0,09000064804f9974
FDA-1996-N-0006-0008,FDA,FDA-1996-N-0006,Response from FDA/CDER to The Procter & Gamble Company,Other,Letter(s),2002-06-26T04:00:00Z,2002,6,,,2015-03-19T20:35:10Z,,0,0,09000064804f9971
FDA-1996-N-0006-0012,FDA,FDA-1996-N-0006,Letter from FDA/CDER to Covington & Burling,Other,Letter(s),2002-06-26T04:00:00Z,2002,6,,,2015-06-19T20:40:35Z,,0,0,09000064804f9975
FDA-1996-N-0006-0004,FDA,FDA-1996-N-0006,Notice of Final Rule re Additional Criteria and Procedures for Classifying Over-the-Counter Drugs as Generally Recognized as Safe and Effective and Not Misbranded,Rule,Final Rule,2002-01-25T05:00:00Z,2002,1,,,2015-05-05T15:08:46Z,,0,0,09000064804f9964